Summary
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract was one of the largest on record in the ongoing research for multiple myeloma treatment. PRA’s clinical team provided enhanced communication and site support, enabling PRA to streamline regulatory document collection to quickly activate sites. Approved by the FDA after a 4-month accelerated approval process, the drug is the first in a new class of anti-cancer agents called proteasome inhibitors.
Register to download
PRA Leads Novel Multiple Myeloma Drug Development
You may also be interested in:
page
Awards and Recognition
PRA and our employees have won numerous awards and accolades in the CRO industry. In 2019, we were named PharmaTimes’ Clinical Company of the…
Case Study
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…
page
Clinical Research Associate
PRA Clinical Research Associates (CRAs) choose one of two career paths. They may work onsite with one of our top pharmaceutical clients. Or they may…